📰 Pooled Data News
Pooled Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pooled Data. Real-time updates on events, politics, business and more.
June 1, 2023
Cosentyx® is the first new biologic treatment for hidradenitis suppurativa in nearly a decade, offering clinically meaningful results across the most debilitating... | June 1, 2023
April 27, 2023
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa •    Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade •    Committee for Medicinal Products for Human Use (CHMP) opinion based...
April 26, 2023
Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade Committee for Medicinal Products for Human Use (CHMP) opinion based on robust Phase
April 26, 2023
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
April 26, 2023
Positive opinion paves way for first new treatment option in hidradenitis suppurativa in nearly a decade Committee for Medicinal Products for Human Use opinion based on robust Phase III data... | April 26, 2023
April 26, 2023
Positive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decade Committee for Medicinal Products for...
November 7, 2022
Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modificationLong-term preservation of native liver in PFIC, improvements in pruritus, bile acids, and... | November 7, 2022
October 21, 2022
/PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...
October 5, 2022
– Seven abstracts accepted, including one oral presentation highlighting long-term data demonstrating Bylvay® (odevixibat) durable efficacy in patients...
October 27, 2021
Data to highlight the safety, tolerability and efficacy of LUPKYNIS in patients with lupus nephritis Aurinia Pharmaceuticals Inc. a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ for the treatment of people with lupus nephritis a serious complication of systemic lupus erythematosus resulting in ...